Hyderabad/ Mumbai, Feb. 2 -- Global pharmaceutical major Lupin Limited has entered into a strategic collaboration with TB Alliance to advance the clinical development and commercialization of the investigational drug Telacebec, aimed at treating tuberculosis (TB) and other serious mycobacterial diseases.
Telacebec, formerly known as Q203, is being developed for multiple indications including TB, leprosy, and Buruli ulcer - diseases that continue to pose major public health challenges, particularly in low- and middle-income countries, Mumbai-based pharmaceutical company said in a release on Monday.
Under the agreement, TB Alliance will continue to lead the clinical development of Telacebec, while Lupin will contribute its global expertise ...